Literature DB >> 17700201

Cisplatin nephrotoxicity: a review.

Xin Yao1, Kessarin Panichpisal, Neil Kurtzman, Kenneth Nugent.   

Abstract

BACKGROUND: Cisplatin is a major antineoplastic drug for the treatment of solid tumors, but it has dose-dependent renal toxicity.
METHODS: We reviewed clinical and experimental literature on cisplatin nephrotoxicity to identify new information on the mechanism of injury and potential approaches to prevention and/or treatment.
RESULTS: Unbound cisplatin is freely filtered at the glomerulus and taken up into renal tubular cells mainly by a transport-mediated process. The drug is at least partially metabolized into toxic species. Cisplatin has multiple intracellular effects, including regulating genes, causing direct cytotoxicity with reactive oxygen species, activating mitogen-activated protein kinases, inducing apoptosis, and stimulating inflammation and fibrogenesis. These events cause tubular damage and tubular dysfunction with sodium, potassium, and magnesium wasting. Most patients have a reversible decrease in glomerular filtration, but some have an irreversible decrease in glomerular filtration. Volume expansion and saline diuresis remain the most effective preventive strategies.
CONCLUSIONS: Understanding the mechanisms of injury has led to multiple approaches to prevention. Furthermore, the experimental approaches in these studies with cisplatin are potentially applicable to other drugs causing renal dysfunction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17700201     DOI: 10.1097/MAJ.0b013e31812dfe1e

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  296 in total

1.  Plasma pharmacokinetics and tissue and brain distribution of cisplatin in musk shrews.

Authors:  Julie L Eiseman; Jan H Beumer; Lora H Rigatti; Sandra Strychor; Kelly Meyers; Samuel Dienel; Charles C Horn
Journal:  Cancer Chemother Pharmacol       Date:  2014-11-15       Impact factor: 3.333

2.  Monitoring renal function during chemotherapy.

Authors:  Louise B Hartlev; Charlotte R Boeje; Henrik Bluhme; Torben Palshof; Michael Rehling
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-06-15       Impact factor: 9.236

3.  Unmodified drug used as a material to construct nanoparticles: delivery of cisplatin for enhanced anti-cancer therapy.

Authors:  Shutao Guo; Lei Miao; Yuhua Wang; Leaf Huang
Journal:  J Control Release       Date:  2013-11-23       Impact factor: 9.776

4.  Pharmacogenetic analysis of irreversible severe cisplatin-induced nephropathy: a case report of a 27-year-old woman.

Authors:  Corine de Jong; Stefan Sanders; Geert-Jan Creemers; Artur M Burylo; Margot Taks; Jan H M Schellens; Maarten J Deenen
Journal:  Br J Clin Pharmacol       Date:  2017-05-31       Impact factor: 4.335

5.  N-heterocyclic carbene gold(I) and silver(I) complexes bearing functional groups for bio-conjugation.

Authors:  Mary E Garner; Weijia Niu; Xigao Chen; Ion Ghiviriga; Khalil A Abboud; Weihong Tan; Adam S Veige
Journal:  Dalton Trans       Date:  2015-01-28       Impact factor: 4.390

6.  Alpha-linolenic acid confers protection on mice renal cells against cisplatin-induced nephrotoxicity.

Authors:  Erman Salih İstifli; Erkan Demir; Halil Mahir Kaplan; Kıvılcım Eren Ateş; Figen Doran
Journal:  Cytotechnology       Date:  2019-08-01       Impact factor: 2.058

Review 7.  Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice.

Authors:  Darren Lars Stirland; Joseph W Nichols; Seiji Miura; You Han Bae
Journal:  J Control Release       Date:  2013-10-02       Impact factor: 9.776

8.  Epoxyeicosatrienoic acids prevent cisplatin-induced renal apoptosis through a p38 mitogen-activated protein kinase-regulated mitochondrial pathway.

Authors:  Yingmei Liu; Xiaodan Lu; Sinh Nguyen; Jean L Olson; Heather K Webb; Deanna L Kroetz
Journal:  Mol Pharmacol       Date:  2013-10-03       Impact factor: 4.436

9.  Cisplatin-induced macroautophagy occurs prior to apoptosis in proximal tubules in vivo.

Authors:  Kosuke Inoue; Hitoshi Kuwana; Yoshiko Shimamura; Koji Ogata; Yoshinori Taniguchi; Toru Kagawa; Taro Horino; Toshihiro Takao; Tatsuhito Morita; Sei Sasaki; Noboru Mizushima; Yoshio Terada
Journal:  Clin Exp Nephrol       Date:  2009-12-15       Impact factor: 2.801

10.  Transplantation of bone marrow-derived MSCs improves cisplatinum-induced renal injury through paracrine mechanisms.

Authors:  Kang Cheng; Partab Rai; Andrei Plagov; Xiqian Lan; Dileep Kumar; Divya Salhan; Shabina Rehman; Ashwani Malhotra; Kuldeep Bhargava; Christopher J Palestro; Sanjeev Gupta; Pravin C Singhal
Journal:  Exp Mol Pathol       Date:  2013-03-25       Impact factor: 3.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.